# Themis Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/themis-bioscience

- Industry: Biotechnology
- Headquarters: Vienna, Austria
- Website: www.themisbio.com
- Total disclosed funding: $63M
- Latest round: Series D (Sep 18, 2019)
- Investors on record: 10

## About

Founded in 2009 and based in Vienna, Austria, Themis Bioscience GmbH operates as a biotechnology company that develops vaccines and therapies for cancer and other infectious diseases.

## Funding rounds

- Series D, Sep 18, 2019, $44M — Ventech, Wellington Partners, Omnes Capital, Merck & Co., Inc., Farallon Capital Management, Cygnum Capital, aws Fondsmanagement, Hadean Ventures, Adjuvant Capital
- Series C, Jan 4, 2018, $12M — Ventech, Wellington Partners, Omnes Capital, aws Austria Wirtschaftsservice Gesellschaft, Cygnum Capital
- Series A, May 23, 2011, $7.2M — Ventech, Omnes Capital

## Investors

- Ventech (https://capitalatlas.ai/funds/ventech) — Series A, Series C, Series D
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series C, Series D
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series C, Series D
- aws Austria Wirtschaftsservice Gesellschaft — Series C
- Cygnum Capital (https://capitalatlas.ai/funds/cygnum-capital) — Series C, Series D
- Merck & Co., Inc. — Series D
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D
- aws Fondsmanagement (https://capitalatlas.ai/funds/aws-fondsmanagement) — Series D
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series D
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series D